Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering - Seite 3
Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the pricing of its “reasonable best efforts” public offering of …